Tuesday, May 21, 2013 Last update: 5:35 AM
Company Tech News as it Breaks
Trade Events
Gilead Sciences, Inc.
News articles for Gilead Sciences, Inc.:
Friday, May 17, 2013
- Gilead Sciences to Present at the 2013 UBS Global Healthcare Conference on Monday, May 20Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the 2013 UBS Global Healthcare Conference in New York. ... read more
Wednesday, May 15, 2013
- Gilead Announces Response Data from Phase 2 Study of Idelalisib for Previously Untreated Chronic Lymphocytic LeukemiaGilead Sciences, Inc. (Nasdaq: GILD) today announced results from a Phase 2 study (Study 101-08) evaluating idelalisib (formerly GS-1101), an investigational, targeted, oral inhibitor of PI3K delta, in ... read more
Tuesday, May 14, 2013
- Gilead Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas. ... read more
Thursday, May 2, 2013
- Gilead Sciences Announces First Quarter 2013 Financial ResultsGilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the quarter ended March 31, 2013. Total revenues for the first quarter of 2013 increased 11 ... read more
Monday, April 29, 2013
- Gilead Receives Complete Response Letters from U.S. Food and Drug Administration for Elvitegravir and CobicistatGilead Sciences, Inc. (Nasdaq: GILD) today announced that the company has received Complete Response Letters from the U.S. Food and Drug Administration (FDA) for its New Drug Applications ... read more
Thursday, April 25, 2013
- Gilead Sciences to Release First Quarter 2013 Financial Results on Thursday, May 2, 2013Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2013 financial results will be released on Thursday, May 2, at 4:05 p.m. Eastern Time. At 4:30 ... read more
Tuesday, April 23, 2013
- Data from Phase 3 Studies of Gilead’s Sofosbuvir for Hepatitis CGilead Sciences, Inc. (Nasdaq: GILD) today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating sofosbuvir, the company’s investigational ... read more
Tuesday, March 26, 2013
- Gilead Announces Update on Phase 3 Study of Oral Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C PatientsGilead Sciences, Inc. (Nasdaq: GILD) today provided an update on ION-1, a Phase 3 clinical trial evaluating a once-daily fixed-dose combination of the nucleotide sofosbuvir and the NS5A ... read more
Friday, March 22, 2013
- European CHMP Adopts Positive Opinion for Stribild®, a Once-Daily, Integrase Inhibitor-Based, Single Tablet Regimen for the Treatment of HIV-1 InfectionGilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted ... read more
Sunday, March 10, 2013
- Gilead’s Ranexa® Reduces Angina Frequency in Study of Chronic Angina Patients With Type 2 DiabetesGilead Sciences, Inc. (Nasdaq: GILD) today announced data from the Phase 4 TERISA (Type 2 Diabetes Evaluation of Ranolazine In Subjects With ... read more
Tuesday, March 5, 2013
- Gilead Announces Full 24-Week Phase 2 Results for Once-Daily Single Tablet HIV Regimen Containing Novel Prodrug Tenofovir Alafenamide (TAF)Gilead Sciences, Inc. (Nasdaq: GILD) today announced detailed 24-week results from a Phase 2 study (Study 102) evaluating a once-daily single tablet regimen containing tenofovir alafenamide (TAF) for ... read more
Friday, March 1, 2013
- Gilead Sciences to Present at the Cowen & Company 33rd Annual Health Care Conference on Monday, March 4Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the Cowen and Company 33rd Annual Health Care Conference in Boston. ... read more
Monday, February 25, 2013
- Gilead Sciences to Present at Two Upcoming Investor ConferencesGilead Sciences, Inc. (Nasdaq: GILD) announced today that the company will be webcasting its corporate presentation at two upcoming investor conferences: the Citi Global Healthcare Conference and the ... read more
Tuesday, February 19, 2013
- Gilead and Teva Reach Settlement Agreement in Viread® Patent LitigationGilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead and Teva Pharmaceuticals have reached an agreement in principle to settle the ongoing patent litigation concerning the patents protecting ... read moreGilead’s Sofosbuvir for Hepatitis C Meets Primary Endpoint in Fourth Pivotal Phase 3 StudyGilead Sciences (Nasdaq:GILD) today announced topline results from the Phase 3 FUSION study evaluating 12- and 16-week courses of therapy with the once-daily nucleotide sofosbuvir plus ribavirin (RBV) ... read more
Friday, February 15, 2013
- Gilead Issues a Voluntary Recall of One Lot of Vistide® (Cidofovir Injection) Due to Presence of Particulate MatterGilead Sciences, Inc. (Nasdaq: GILD) today announced it is voluntarily recalling lot B120217A of Vistide® (cidofovir injection) to the user level due to the presence of particulate matter found in ... read more
Monday, February 11, 2013
- Gilead Sciences to Present at Two Upcoming Investor ConferencesGilead Sciences, Inc. (Nasdaq: GILD) announced today that the company will be webcasting its corporate presentation at two upcoming investor conferences: the BIO CEO & Investor Conference and ... read more
Friday, February 8, 2013
- Gilead Sciences Completes Acquisition of YM BioSciencesGilead Sciences, Inc. (Nasdaq: GILD) today announced that it has completed its acquisition of YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM). ... read more
Monday, February 4, 2013
- Gilead Sciences Announces Fourth Quarter and Full Year 2012 Financial ResultsGilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2012. Total revenues for the fourth quarter of 2012 increased ... read moreGilead Announces Sustained Virologic Response Rates from Two Phase 3 Studies of Sofosbuvir for Hepatitis CGilead Sciences (Nasdaq:GILD) today announced topline results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide sofosbuvir in combination with ribavirin ... read more